Insulin resistance and lipid metabolism

American Journal of Cardiology

Volumn 84, Issue 1 A, 1999, Pages 28-32

  Howard, Barbara V ^a  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; DYSLIPIDEMIA; ENZYME ACTIVITY; EXERCISE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PARTICLE SIZE; POSTPRANDIAL STATE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

EID: 0033536189     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(99)00355-0     Document Type: Conference Paper

References (25)

1. Orchard T.J., Becker D.J., Bates M., Kuller L.H., Drash A.L. Plasma insulin and lipoprotein concentrations an atherogenic association? Am J Epidemiol. 118:1983;326-337.
2. Howard B.V., Knowler W.C., Vasquez B., Kennedy A.L., Pettitt D.J., Bennett P.H. Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population. Comparison of diabetics and nondiabetics. Arteriosclerosis. 4:1984;462-471.
3. Zavaroni I., Dall'Aglio E., Alpi O., Bruschi F., Bonora E., Pezzarossa A., Butturini U. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 55:1985;259-266.
4. Cambien F., Warnet J.M., Eschwege E., Jacqueson A., Richard J.L., Rosselin G. Body mass, blood pressure, glucose, and lipids. Does plasma insulin explain their relationships? Arteriosclerosis. 7:1987;197-202.
5. Donahue R.P., Orchard T.J., Becker D.J., Kuller L.H., Drash A.L. Sex differences in the coronary heart disease risk profile: a possible role for insulin. The Beaver County Study. Am J Epidemiol. 125:1987;650-657.
6. Haffner S.M., Fong D., Hazuda H.P., Pugh J.A., Patterson J.K. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism. 37:1988;338-345.
7. Modan M., Halkin H., Lusky A., Segal P., Fuchs Z., Chetrit A. Hyperinsulinemia is characterized by jointly disturbed plasma VLDL, LDL, and HDL levels. A population-based study. Arteriosclerosis. 8:1988;227-236.
8. McKeigue P.M., Miller G.J., Marmot M.G. Coronary heart disease in south Asians overseas a review . J Clin Epidemiol. 42:1989;597-609.
9. Burchfiel C.M., Hamman R.F., Marshall J.A., Baxter J., Kahn L.B., Amirani J.J. Cardiovascular risk factors and impaired glucose tolerance The San Luis Valley Diabetes Study . Am J Epidemiol. 131:1990;57-60.
10. Manolio T.A., Savage P.J., Burke G.L., Liu K.A., Wagenknecht L.E., Sidney S., Jacobs D.R. Jr, Roseman J.M., Donahue R.P., Oberman A. Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. Arteriosclerosis. 10:1990;430-436.
11. Reaven G.M., Chen Y.-D.I., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small dense low density lipoprotein particles. J Clin Invest. 92:1993;141-146.
12. Abbott W.G.H., Lillioja S., Young A.A., Zawadzki J.K., Yki-Jarvinen H., Christin L., Howard B.V. Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes. 36:1987;897-904.
13. Howard B.V. Insulin actions in vivo insulin and lipoprotein metabolism . Alberti K.G.M.M., Zimmet P., DeFronzo R.A., Keen H. International Textbook of Diabetes Mellitus. 1997;John Wiley and Sons, New York.
14. Austin M.A., King M.-C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype a proposed genetic marker for coronary heart disease risk . Circulation. 82:1990;495-506.
15. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H.-J., Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 9:1989;579-592.
16. Haffner S.M., Morales P.A., Stern M.P., Gruber M.K. Lp(a) concentrations in NIDDM. Diabetes. 41:1992;1267-1272.
17. Jeppesen J., Hollenbeck C.B., Zhou M.-Y., Coulston A.M., Jones C., Chen Y.D.I., Reaven G.M. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol. 15:1995;320-324.
18. Zilversmit D.B. Atherogenesis a postprandial phenomenon . Circulation. 60:1979;473-485.
19. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1993;1595-1607.
20. Goldberg R, Sacks F, Howard B, Moye L, Cole T, Mellies MJ, Howard J. Diabetic response to pravastatin during the CARE study. (Abstr.) Circulation 1996;94(suppl I):I-540.
21. Ronnemaa T., Marniemi J., Puukka P., Kuusi T. Effects of long-term physical exercise on serum lipids, lipoproteins and lipid metabolizing enzymes in type 2 (non-insulin-dependent) diabetic patients. Diabetes Res. 7:1988;79-84.
22. Nagi D.K., Yudkin J.S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects a study of 2 ethnic groups . Diabetes Care. 16:1993;621-629.
23. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 333:1995;541-549.
24. Kumar S., Boulton A.J.M., Beck-Nielsen H., Berthezene F., Muggeo M., Persson B., Spinas G.A., Donoghue S., Lettis S., Stewart-Long P. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 39:1996;701-709.
25. Tack C.J.J., Smits P., Demacker P.N.M., Stalenhoef A.F.H. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 21:1998;796-799.